What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?

This publication has 14 references indexed in Scilit:

• Cost and utilisation of pharmaceuticals in Sweden
  Health Policy, 1997
• Pharmaceutical cost containment and innovation in the United States
  Health Policy, 1997
• Do Open Formularies Increase Access To Clinically Useful Drugs?
  Health Affairs, 1996
• The 1996 Pricing and Reimbursement Policy in The Netherlands
  PharmacoEconomics, 1996
• Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany
  PharmacoEconomics, 1996
• Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia
  New England Journal of Medicine, 1994
• Cost containment and health care reform: a study of the European Union
  Health Policy, 1994
• Recent Public Policies in The Netherlands to Control Pharmaceutical Pricing and Reimbursement
  PharmacoEconomics, 1994
• Regression Analysis for Correlated Data
  Annual Review of Public Health, 1993
• Reforms as experiments.
  American Psychologist, 1969